Real-world efficacy and safety of anlotinib in Chinese solid tumors patients with liver metastases: a multicenter retrospective study
Frontiers in Pharmacology · 15.05.2026 · 17
DOI: 10.3389/fphar.2026.1639934 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 15.05.2026. Verfasst von Yanru Qin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Liver metastases are associated with dismal prognosis in solid tumors. This retrospective study evaluated the efficacy and safety of anlotinib in patients with solid tumors and liver metastases in the real-world setting.
Methods
Patient data from 5 centers in China were reviewed, and patients treated with anlotinib-based therapy were included in a single group. Tumor response was evaluated according to the Response Evaluation Criteria in Solid Tumors version 1.1. The primary outcomes were objective response rate (ORR) and progression-free survival (PFS). Secondary outcomes included hepatic ORR (hORR), hepatic PFS (hPFS), overall survival (OS), duration of response (DOR), and safety.
Results
Between January 2020 and February 2023, 475 patients were included. Median PFS was 5.80 months (95% confidence interval [CI]: 5.27-6.60). The ORR and hORR were 17.89% and 18.74%, with a median DOR of 8.63 months (95% CI: 6.57 to not reached [NR]) and 8.80 months (95% CI: 7.51-NR), respectively. Median hPFS and OS were 6.03 months (95% CI: 5.33-6.60) and 9.53 months (95% CI: 8.40-NR), respectively. Similar median PFS, hPFS, and OS were observed across different tumor types. Patients with body mass index (BMI) <18.5 kg/m 2 had significantly shorter median PFS and hPFS than those with BMI of 18.5-23.9 kg/m 2 and ≥24.0 kg/m 2 . The incidence of any-grade adverse events was 19.58%, with the most common being hematological toxicities (14.11%). Grade ≥3 adverse events occurred in 1.68% of the patients.
Discussion
These findings suggest the clinical benefits of anlotinib for the treatment of solid tumors with liver metastases, with a manageable safety profile.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
- Department I of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
- Department of Abdominal Radiotherapy, Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Hangzhou, China.
- Department of Medical Oncology, Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital), Jinan, China.
Zitieren
APA
Qin, Y., Zhu, Y., Zhuo, M., Xu, X., & Wang, Z. (2026). Real-world efficacy and safety of anlotinib in Chinese solid tumors patients with liver metastases: a multicenter retrospective study. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1639934
Vancouver
Qin Y, Zhu Y, Zhuo M, Xu X, Wang Z. Real-world efficacy and safety of anlotinib in Chinese solid tumors patients with liver metastases: a multicenter retrospective study. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1639934
BibTeX
@article{Qin2026,
author = {Qin, Yanru and Zhu, Yujia and Zhuo, Minglei and Xu, Xiaoxian and Wang, Zhehai},
title = {Real-world efficacy and safety of anlotinib in Chinese solid tumors patients with liver metastases: a multicenter retrospective study},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1639934}
}
EUVIMED